Search This Blog

Friday, January 29, 2021

AIM ImmunoTech in Pact for Intranasal Safety Study of Ampligen

 AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a sponsorship agreement with the Centre for Human Drug Research (CHDR) for the proposed AMP-COV-100 (CHDR2049) clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, a critical step in the company’s ongoing efforts to develop Ampligen as a COVID-19 treatment.

CHDR, an independent institute located in Leiden in the Netherlands, will conduct and manage the proposed clinical study, titled “A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subjects.”

Current study plans call for the enrollment of eight healthy subjects in each of four Ampligen treatment groups and one placebo group, for a total of 40 healthy subjects. They will receive intranasal dosing every other day for 13 days, for a total of seven doses each.

AIM is funding the clinical study. The company is working to finalize the study protocol and will announce new information as it becomes available.

https://www.biospace.com/article/releases/aim-immunotech-enters-into-agreement-for-proposed-intranasal-safety-study-of-ampligenaim-is-working-to-develop-an-effective-covid-19-intranasal-therapy/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.